Dendritic cells (DCs) are highly mobile antigen-presenting cells that use a coordinated trafficking system to ensure that they are present in the right place and at the right time to induce proper immune responses 1 . Before encountering foreign antigens, DCs reside as sentinels in the peripheral tissues. However, after antigen exposure, DCs migrate from the peripheral tissues to lymphoid organs, where they activate T cells. To exit the periphery, DCs must migrate toward and enter the initial lymphatics 2,3 . This is an active process that involves chemokines and adhesion molecules [4] [5] [6] [7] [8] . Transmission electron microscopy has shown that DCs must undergo considerable morphological changes to pass through endothelial junctions 9,10 . Non-muscle myosin II is needed to propel DC cellular bodies forward and enable them to pass through narrow gaps 11 . However, it is still unknown how DCs interact with the lymphatic endothelium during transmigration and whether the lymphatics, in turn, control and affect DC mobilization to coordinate their cytoskeletal dynamics, including contraction and adhesion disassembly.
A r t i c l e s
Dendritic cells (DCs) are highly mobile antigen-presenting cells that use a coordinated trafficking system to ensure that they are present in the right place and at the right time to induce proper immune responses 1 . Before encountering foreign antigens, DCs reside as sentinels in the peripheral tissues. However, after antigen exposure, DCs migrate from the peripheral tissues to lymphoid organs, where they activate T cells. To exit the periphery, DCs must migrate toward and enter the initial lymphatics 2, 3 . This is an active process that involves chemokines and adhesion molecules [4] [5] [6] [7] [8] . Transmission electron microscopy has shown that DCs must undergo considerable morphological changes to pass through endothelial junctions 9, 10 . Non-muscle myosin II is needed to propel DC cellular bodies forward and enable them to pass through narrow gaps 11 . However, it is still unknown how DCs interact with the lymphatic endothelium during transmigration and whether the lymphatics, in turn, control and affect DC mobilization to coordinate their cytoskeletal dynamics, including contraction and adhesion disassembly.
Semaphorins were initially identified as axonal guidance cues that determine the direction and migration of neurons during neurogenesis 12 . In addition, they have diverse and important functions in other physiological processes, including heart development 13 , vascular growth 14 , tumor progression 15, 16 and immune responses 17 . Several semaphorins have costimulatory molecule-like activities that promote the activation of B cells 18 , T cells 19 , DCs 20 and macrophages 21 through cell-cell interactions. In the nervous system, semaphorins regulate cell motility and morphology through interaction with receptors of the plexin family 22 . A similar role for semaphorins in regulating the migration of cells of the immune response has been proposed. Among the plexin family members, plexin-A1 represents the main receptor for class III and class VI semaphorins. Together with ligand-binding neuropilins, plexin-A1 transduces repulsive axon-guidance signals for soluble class III semaphorins 23 . Independently of neuropilins, plexin-A1 functions in neurogenesis and cardiogenesis as a receptor for the class VI transmembrane semaphorins Sema6C and Sema6D 13, 24 . In the immune system, plexin-A1 is expressed specifically in DCs, and it may facilitate DC-mediated stimulation of T cells 25 . Plexin-A1-deficient (Plxna1 −/− ) mice have severe defects in antigen-specific T cell responses 20 . However, it is still unclear whether semaphorins physiologically regulate the migration of cells of the immune response via plexin receptors.
Here we demonstrate that plexin-A1 has a crucial role in DC trafficking, particularly during entry into lymphatics. Specifically, we show that Sema3A produced in the lymphatics functioned as a ligand for the plexin-A1-neuropilin 1 (NRP1) receptor complex expressed by DCs. Furthermore, we demonstrate that Sema3A acted on the rear side of DCs, where plexin-A1 is localized. Sema3A induced A r t i c l e s phosphorylation of the myosin light chain (MLC) to promote actomyosin contraction, which resulted in more DC transmigration as these cells passed through narrow gaps.
RESULTS
Impaired DC trafficking to draining lymph nodes in Plxna1 −/− mice Antigen-specific T cell generation is severely impaired in Plxna1 −/− mice 20 . However, it is unclear how plexin-A1 is involved in antigenspecific T cell priming. To investigate these mechanisms in greater detail, we activated OT-II T cells (with an ovalbumin (OVA)-specific T cell antigen receptor) 26 in wild-type and Plxna1 −/− mice. OT-II T cells labeled with the cytosolic dye CFSE proliferated extensively after subcutaneous administration of OVA peptides in complete Freund's adjuvant to wild-type recipient mice (Fig. 1a) . In contrast, antigen-specific proliferative responses were much lower when we transferred OT-II T cells into Plxna1 −/− recipient mice (Fig. 1a) , which confirmed the importance of plexin-A1 in antigen-specific T cell responses (Supplementary Fig. 1a) .
Antigen-specific T cells are primed in the draining lymph nodes via encounters with antigen-pulsed DCs 27 . To examine the effect of Plxna1 −/− DCs on DC-T cell interactions in the draining lymph nodes, we obtained OVA-pulsed DCs from wild-type or Plxna1 −/− mice, labeled them with the cell-tracking dye CMTMR (5-(and-6)-(((4-chloromethyl)benzoyl) amino)tetramethylrhodamine), injected them into the footpads of wild-type recipient mice and analyzed the popliteal lymph nodes by two-photon microscopy. When we injected wild-type DCs into the footpads, CMTMR-labeled DCs were abundantly distributed and localized throughout the T cell area of the draining lymph nodes (Fig. 1b) . In contrast, when we injected Plxna1 −/− DCs, we found only minimal DCs in the draining lymph nodes of recipient mice (Fig. 1b) , which indicated that Plxna1 −/− DCs had impaired migratory abilities. To quantitatively compare the in vivo migratory activities of wild-type and Plxna1 −/− DCs, we injected CFSE-labeled DCs into the footpads of wild-type mice and examined their arrival in the draining lymph nodes. Plxna1 −/− DCs showed impaired migratory activity compared with that of wild-type DCs ( Fig. 1c and Supplementary Fig. 1b) . We also analyzed the migration of endogenous DCs under steady-state conditions. Plxna1 −/− mice had fewer CD11c + major histocompatibility complex class II-high and CD11c + CD4 − CD8 − migratory DC subsets in the skin-draining lymph nodes 6, 28 (Supplementary Fig. 1c) . Because the expression of plexin-A1 increased during DC maturation (Supplementary Fig. 2b) , we investigated the trafficking of endogenous DCs to the draining lymph nodes under inflammatory conditions. We applied fluorescein isothiocyanate (FITC) epicutaneously to an area of skin that drains to the brachial lymph nodes and counted FITC + DCs in the draining lymph nodes 29, 30 . We found considerably less accumulation of FITC + DCs in brachial lymph nodes in Plxna1 −/− mice than in wild-type mice (Fig. 1d) . Collectively these findings indicate that plexin-A1 is critically involved in DC trafficking and that impaired DC migration is the main reason for defective T cell priming in Plxna1 −/− mice.
Impaired transmigration of Plxna1 −/− DCs To determine which step requires plexin-A1 during DC trafficking from the peripheral tissues to the lymphatics 3 , we studied antigen uptake, interstitial migration toward the lymphatics in response to chemokines and transmigration across the lymphatics in greater detail (Supplementary Fig. 3 ). We did not find differences between wildtype and Plxna1 −/− DCs in their antigen uptake (Fig. 2a) . In addition, there were no differences in the ability of DCs to migrate in response to the chemokines CCL19, CCL21 or CXCL12 in Transwell systems (Fig. 2b) , or in their ability to sense direction in a chemokine-gradient assay ( Fig. 2c and Supplementary Movie 1) . Consistent with those findings, wild-type and Plxna1 −/− DCs had similar expression of the chemokine receptors CCR7 and CXCR4 (Fig. 2d) . These results indicate that plexin-A1 is not required for antigen uptake or chemokine responsiveness during migration.
To assess the role of plexin-A1 in the transmigration process in vivo, we adoptively transferred CFSE-labeled wild-type or Plxna1 −/− DCs into the dermis of oxazolone-treated mice and assessed the fate of emigrating DCs 7 . Large numbers of Plxna1 −/− DCs were retained along lymphatics positive for the lymphatic endothelial cell marker LYVE-1 in the dermis of recipient mice 24 h after adoptive transfer (Fig. 3a) , an activity we did not observe with wild-type DCs. This indicated that Plxna1 −/− DCs have impaired transmigration across the lymphatics.
By time-lapse imaging we investigated whether plexin-A1 deficiency in DCs affected the initial contacts between DCs and lymphatic endothelial cells. Wild-type DCs interacted with endothelial cells at the cell-cell junctions of lymphatic endothelial cells and transmigrated across the endothelial cells ( Fig. 3b and Supplementary Movie 2) . Although Plxna1 −/− DCs actively moved, extended their dendrites and contacted the lymphatic endothelial cells to the same degree as wild-type DCs did, they did not transmigrate across the lymphatic A r t i c l e s endothelial cells ( Fig. 3b and Supplementary Movie 2), To confirm that observation, we added CFSE-labeled DCs onto monolayers of lymphatic endothelial cells stained with the F-actin marker phalloidin and monitored these cells by confocal z-stack imaging. We observed wild-type DCs from the top to the bottom of the endothelial cells. In contrast, although Plxna1 −/− DCs were able to attach to the lymphatic endothelial cells, they could not transmigrate across these cells ( Fig. 3c and Supplementary Movie 3). Additionally, Plxna1 −/− DCs showed significantly impaired chemokineinduced transmigration across endothelial cell monolayers in Transwell systems (Fig. 3d) . Together these results suggest that plexin-A1 has an important role in the transmigration of DCs across the lymphatics.
Sema3A is responsible for plexin-A1-dependent DC trafficking
Plexin-A1 is a receptor component for two types of semaphorins: a secreted class III semaphorin, Sema3A, and class VI transmembrane semaphorins, Sema6C and Sema6D ( Supplementary Fig. 2a) . Notably, Sema3A, Sema6C and Sema6D were all expressed in lymphatic endothelial cells (Supplementary Fig. 2b ). To determine which interaction was responsible for the defects in Plxna1 −/− DCs, we adoptively transferred DCs from wild-type mice into Sema3a −/− mice 31 , Sema6c −/− mice ( Supplementary Fig. 4 ) and Sema6d −/− mice ( Supplementary Fig. 5 ). DCs from wild-type mice showed impaired migration to the draining lymph nodes when transferred into Sema3a −/− recipient mice (Fig. 4a) . However, there were no defects in the migration of wild-type DCs in Sema6c −/− or Sema6d −/− recipient mice (Fig. 4a) . These results suggest that Sema3A in the lymphatics is indispensable for DC trafficking. Consistent with that, the Sema3A receptor component NRP1 was expressed in DCs ( Supplementary Fig. 2b ). In addition, DCs from Nrp1 sema− knockin mice 32 , in which the Sema3A-binding sites are defective, showed impaired trafficking to the draining lymph nodes when transferred into wild-type recipient mice (Fig. 4b, left) . We confirmed those findings by in vitro transmigration assays in a lymphatic endothelial cell monolayer and found that DCs from Nrp1 sema− knock-in mice showed impaired transmigration (Fig. 4b, right) , similar to that of DCs from Plxna1 −/− mice (Fig. 3d) . Although DCs expressed Sema6D (Supplementary Fig. 2b ), DCs from Sema6d −/− mice did not show any defects (data not shown). These results indicate that NRP1 expression in DCs is required for DC trafficking. Consistent with those results, Sema3a −/− and Nrp1 sema− knock-in mice had defects in T cell priming (Fig. 4c ) similar to those of Plxna1 −/− mice ( Supplementary Fig. 1a) , whereas neither Sema6c −/− nor Sema6d −/− mice had any defects in antigen-specific T cell priming (Fig. 4c) . Collectively these results indicate that Sema3A is a functional ligand for plexin-A1 during the trafficking of DCs into the lymph nodes, but Sema6C and Sema6D are not.
Sema3A acts on the rear side of DCs Sema3A has been identified as a chemorepellent factor that guides the direction of neurons 12 , whereas here we have shown that it promotes DC trafficking. Therefore, we hypothesized that cell polarity generated by chemokines during DC migration is critical for the effects induced by Sema3A. To determine the mechanism by which Sema3A
regulates DC migration, we did chemotaxis assays by adding Sema3A to the lower or upper chamber of a Transwell system in the presence or absence of chemokines. In the absence of chemokines, Sema3A did not show an effect on spontaneous DC migration. In contrast, in the presence of chemokines, DC chemotaxis was enhanced in Transwell systems when we added Sema3A to the upper chamber, where Sema3A acted on the rear side of DCs, but not when we added Sema3A to the lower chamber (Fig. 5a) . In two-dimensional directional migration assays evaluated by the EZ-TAXIScan device, Sema3A increased the motility and speed of DCs when it was applied against a chemokine gradient ( Fig. 5b and Supplementary Movie 4) . Consistent with those findings, plexin-A1 localized at the trailing edge but not at the leading edge of migrating DCs, where we readily observed actin polymerization (Fig. 5c,d and Supplementary Movie 5). These results suggest that the effects of Sema3A depend on the polarity of migrating DCs.
Sema3A induces actomyosin contraction via myosin II activity
Myosin II, which is regulated by phosphorylation of MLC 33 and the Rho kinase ROCK, is involved in DC trafficking 11 . The localization Figure 4 Sema3A-NRP1- . Myosin II is believed to be required for squeezing of the cell body and induction of actomyosin contraction when cells pass through narrow gaps or constricted areas 11 . In addition, myosin II has been linked to Sema3A-mediated axon retraction 34, 35 . Given those findings, we investigated whether Sema3A affects the function of myosin II in DCs during their mobilization. As expected, MLC phosphorylation was enhanced in DCs stimulated with recombinant Sema3A (Fig. 6a) , and we did not observe this effect in Plxna1 −/− DCs (Supplementary Fig. 6 ), which indicated that Sema3A promotes MLC phosphorylation via plexin-A1. In three-dimensional collagen matrices, which have been used to model passage through constricted areas in vitro, Sema3A increased the speed of DCs and the motile DC fraction (Fig. 6b and Supplementary Movie 6) and significantly enhanced DC transmigration, and this effect was abolished in Plxna1 −/− DCs (Fig. 6c) . In addition, the Sema3A-induced DC transmigration in collagen matrices (Fig. 6d, left) or across lymphatic endothelial cell monolayers (Fig. 6d, right) was abolished in DCs treated with either the myosin II inhibitor blebbistatin or the ROCK inhibitor Y-27632. Collectively these results suggest that Sema3A induces actomyosin contraction in DCs during plexin-A1-mediated transmigration (Supplementary Fig. 7 ).
DISCUSSION
Although semaphorins were originally identified as axonal guidance cues that regulate cell motility and morphology, accumulating evidence indicates that they also function as immunoregulatory molecules. So far, most functional studies of semaphorins and their receptors have focused on their costimulatory effects on cells of the immune response 17 . Although the nervous and immune systems have considerable crosstalk, and their molecular repertories and machineries overlap 36 , it is still unknown whether semaphorins function as guidance cues that physiologically regulate the movement of cells of the immune response. Here we have demonstrated that semaphorin signals are crucial for DC trafficking, particularly for the entry of DCs into the lymphatics. Furthermore, we have highlighted a previously unknown mechanism for DC transmigration across the lymphatics in which Sema3A promotes actomyosin contraction at the trailing edge of migrating DCs so they can pass through narrow gaps. To exit peripheral tissues, DCs must migrate toward and enter the initial lymphatics. Although it has been assumed that the migration of DCs into the lymphatics is an indolent process, we have provided evidence that Sema3A expressed in lymphatics is crucially involved in DC transmigration. Furthermore, we found that plexin-A1 localized at the trailing edge of migrating DCs, the area responsible for actomyosin contraction. Many factors, including chemokines 6, 8 , inflammatory molecules 5, 37, 38 and adhesion molecules 7 , have been reported to participate in DC transmigration. However, in our study, neither chemokine responsiveness nor the expression of chemokine receptors was affected in the absence of plexin-A1. The adhesion of DCs to extracellular matrix proteins or to lymphatic endothelial cells was similar in wild-type and Plxna1 −/− DCs, and the expression of integrins was similar in wild-type and Plxna1 −/− DCs (data not shown). In addition, there were no differences between wild-type and Plxna1 −/− DCs in their secretion of the immature form of matrix metalloproteinase 9 and tumor necrosis factor (data not shown). Thus, these results not only indicate that DC transmigration is regulated by active mechanisms but also identify a previously unknown mechanism for this process.
Plexin-A1 is a chief receptor component not only for the soluble semaphorin Sema3A, in association with the receptor NRP1, but also for the transmembrane-type semaphorins Sema6C and Sema6D. We have determined here that Sema3A produced in the lymphatics functioned as a ligand for the plexin-A1-NRP1 receptor complex expressed in DCs, which indicates that the Sema3A-NRP1-plexin-A1 pathways have important roles in DC migration by mediating interactions between DCs and lymphatic endothelial cells. However, it is still unclear why Sema3A, but not Sema6C or Sema6D, is involved in Sema3A-Fc this process. One possible explanation is that signaling downstream of plexin-A1 is modified by the presence of NRP1 in the receptor. Alternatively, differences in the effects may be due to the fact that Sema3A is a soluble protein. In contrast, Sema6C and Sema6D are membrane-bound semaphorins, which may prevent them from functioning at critical interaction sites between transmigrating DCs and endothelial cells.
Members of the Rho family of small GTPases (Rac1, Cdc42 and RhoA) regulate cell movement by altering actin assembly, adhesion and actomyosin contraction 39 . Among those molecules, Rac1 is required for the generation of actin-rich lamellipodial protrusions and integrin-mediated adhesion 40 . In contrast, RhoA activates ROCK and subsequently activates non-muscle myosin II, which promotes an actomyosin contractile force 41 . Mesenchymal cell movement depends on integrin-mediated traction forces. In contrast, amoeboid cell movement, particularly in three-dimensional environments, does not require integrins. Instead, ROCK-and myosin II-dependent contraction is crucially required for passage through narrow gaps 11 . Consistent with that, we found that Sema3A promoted actomyosin contraction by inducing MLC phosphorylation. Furthermore, this effect was attenuated by blockade of ROCK activity, which indicates that the Sema3A-induced effects on myosin II activity require RhoA-ROCK-mediated signals. In neurons, Sema3A induces the local translation of RhoA in neuronal dendrites 42 , and knockdown of RhoA mediated by small interfering RNA blocks Sema3A-mediated collapse of the growth cone 43 . In addition, Sema3A induces MLC phosphorylation, and inhibiting myosin II activity blocks Sema3A-mediated axon retraction 34, 35 . These findings indicate that Sema3A-mediated signals promote actomyosin contractile forces through RhoA-dependent activation of myosin II in cells of both the immune and nervous systems.
DCs must pass through various environments. In tissues such as fibroblastic reticular tissues and inner vessel walls, DCs use integrinmediated attachment and contractile forces for cell movement. In contrast, in constricted areas, DCs use myosin II-mediated actomyosin contractile forces to move forward, because such tissues confine and mechanically anchor cell bodies 44, 45 . During DC transmigration, at least three sequential mechanisms may be required. First, DCs must form a lamellipodial protrusion at the leading edge in response to chemokines, which are the driving signal for forward movement. Second, DCs must contract and squeeze their bodies by actomyosin contraction to pass through narrow gaps. Third, after DCs are exposed to the luminal side, the trailing edge must detach from endothelial cells for DCs to enter the circulation. Here we have shown that Sema3A acts on the rear side of DCs through plexin-A1 to promote DC migration. These findings indicate that Sema3A-mediated signals are involved not only in actomyosin contraction but also in the disassembly of adhesive components at the trailing edge during DC transmigration. Indeed, myosin II promotes a traction stress that facilitates detachment at the trailing edge 46, 47 , which suggests that detachment can be induced by Sema3A-mediated actomyosin contraction. However, Sema3A can inhibit integrin-mediated adhesion by inducing sequestration of the phosphatidylinositol phosphate kinase type I isoform PIPKIγ661 from talin, a chief component of focal adhesion 48 . In this context, it is plausible that Sema3A has dual or integral roles in regulating actomyosin contraction and adhesion disassembly at the trailing edge during the course of DC transmigration.
In conclusion, our study has not only shown the importance of Sema3A-mediated signals in DC trafficking, particularly for passage through the lymphatics, but has also identified a previously unknown mechanism that promotes actomyosin contraction at the trailing edge of migrating cells. As semaphorins are also expressed in vascular endothelial cells 14, 16 , it is plausible that they have a role in leukocyte extravasation or cancer metastasis. Additional detailed studies are needed to gain insight into these mechanisms, which have the potential to regulate immune reactions for the treatment of autoimmune, allergic and infectious diseases and inhibition of cancer metastasis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
